Antimicrobial resistance of Acinetobacter spp. in Europe
Bacteria of the genus Acinetobacter are ubiquitous in nature. These organisms were invariably susceptible to many antibiotics in the 1970s. Since that time, acinetobacters have emerged as multiresistant opportunistic nosocomial pathogens. The taxonomy of the genus Acinetobacter underwent extensive r...
Gespeichert in:
| Veröffentlicht in: | Clinical microbiology and infection 2004-08, Vol.10 (8), p.684-704 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 704 |
|---|---|
| container_issue | 8 |
| container_start_page | 684 |
| container_title | Clinical microbiology and infection |
| container_volume | 10 |
| creator | Van Looveren, M. Goossens, H. |
| description | Bacteria of the genus Acinetobacter are ubiquitous in nature. These organisms were invariably susceptible to many antibiotics in the 1970s. Since that time, acinetobacters have emerged as multiresistant opportunistic nosocomial pathogens. The taxonomy of the genus Acinetobacter underwent extensive revision in the mid-1980s, and at least 32 named and unnamed species have now been described. Of these, Acinetobacter baumannii and the closely related unnamed genomic species 3 and 13 sensu Tjernberg and Ursing (13TU) are the most relevant clinically. Multiresistant strains of these species causing bacteraemia, pneumonia, meningitis, urinary tract infections and surgical wound infections have been isolated from hospitalised patients worldwide. This review provides an overview of the antimicrobial susceptibilities of Acinetobacter spp. in Europe, as well as the main mechanisms of antimicrobial resistance, and summarises the remaining treatment options for multiresistant Acinetobacter infections. |
| doi_str_mv | 10.1111/j.1469-0691.2004.00942.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66774647</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1198743X14627658</els_id><sourcerecordid>17794424</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5592-dd6ff4304c55396ace3e8d05aae7cbe272cd69ebfe623ce265e34add93a6b2723</originalsourceid><addsrcrecordid>eNqNkctOAyEUhonRWK2-gpmN7mbkNlASN7Wpl6TGjSbuCANnEprpzAhTL28vtY0ulQ2Q8_3A-UAoI7ggaVwuC8KFyrFQpKAY8wJjxWnxsYeOfgr7aU3UJJecvYzQcYxLjDFljB-iESkZJkKSIzSZtoNfeRu6ypsmCxB9HExrIevqbGp9C0NXGTtAyGLfF5lvs_k6dD2coIPaNBFOd_MYPd_Mn2Z3-eLx9n42XeS2LBXNnRN1zRnmacuUMBYYTBwujQFpK6CSWicUVDUIyixQUQLjxjnFjKhSlY3RxfbcPnSva4iDXvlooWlMC906aiGk5ILLP0EipeKc8gROtmBqOsYAte6DX5nwqQnWG716qTcW9cai3ujV33r1R4qe7e5YVytwv8GdzwSc7wATrWnqkFT6-MsJzARVOHFXW-7dN_D57wfo2eIhLVL8ehuHZP7NQ9DReki_5nwAO2jX-b-b-QJc1qpq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17794424</pqid></control><display><type>article</type><title>Antimicrobial resistance of Acinetobacter spp. in Europe</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Van Looveren, M. ; Goossens, H.</creator><creatorcontrib>Van Looveren, M. ; Goossens, H. ; the ARPAC Steering Group ; ARPAC Steering Group</creatorcontrib><description>Bacteria of the genus Acinetobacter are ubiquitous in nature. These organisms were invariably susceptible to many antibiotics in the 1970s. Since that time, acinetobacters have emerged as multiresistant opportunistic nosocomial pathogens. The taxonomy of the genus Acinetobacter underwent extensive revision in the mid-1980s, and at least 32 named and unnamed species have now been described. Of these, Acinetobacter baumannii and the closely related unnamed genomic species 3 and 13 sensu Tjernberg and Ursing (13TU) are the most relevant clinically. Multiresistant strains of these species causing bacteraemia, pneumonia, meningitis, urinary tract infections and surgical wound infections have been isolated from hospitalised patients worldwide. This review provides an overview of the antimicrobial susceptibilities of Acinetobacter spp. in Europe, as well as the main mechanisms of antimicrobial resistance, and summarises the remaining treatment options for multiresistant Acinetobacter infections.</description><identifier>ISSN: 1198-743X</identifier><identifier>EISSN: 1469-0691</identifier><identifier>DOI: 10.1111/j.1469-0691.2004.00942.x</identifier><identifier>PMID: 15301671</identifier><language>eng</language><publisher>Oxford, UK: Elsevier Ltd</publisher><subject>Acinetobacter ; Acinetobacter - classification ; Acinetobacter - drug effects ; Acinetobacter baumannii ; Acinetobacter Infections - epidemiology ; Acinetobacter Infections - microbiology ; Anti-Bacterial Agents - pharmacology ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; antimicrobial resistance ; Biological and medical sciences ; carbapenems ; Drug Resistance, Bacterial ; Europe ; Europe - epidemiology ; Humans ; Infectious diseases ; Medical sciences ; Microbial Sensitivity Tests ; Pharmacology. Drug treatments ; Population Surveillance ; review ; surveillance</subject><ispartof>Clinical microbiology and infection, 2004-08, Vol.10 (8), p.684-704</ispartof><rights>2004 European Society of Clinical Infectious Diseases</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5592-dd6ff4304c55396ace3e8d05aae7cbe272cd69ebfe623ce265e34add93a6b2723</citedby><cites>FETCH-LOGICAL-c5592-dd6ff4304c55396ace3e8d05aae7cbe272cd69ebfe623ce265e34add93a6b2723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1469-0691.2004.00942.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1469-0691.2004.00942.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16036290$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15301671$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Van Looveren, M.</creatorcontrib><creatorcontrib>Goossens, H.</creatorcontrib><creatorcontrib>the ARPAC Steering Group</creatorcontrib><creatorcontrib>ARPAC Steering Group</creatorcontrib><title>Antimicrobial resistance of Acinetobacter spp. in Europe</title><title>Clinical microbiology and infection</title><addtitle>Clin Microbiol Infect</addtitle><description>Bacteria of the genus Acinetobacter are ubiquitous in nature. These organisms were invariably susceptible to many antibiotics in the 1970s. Since that time, acinetobacters have emerged as multiresistant opportunistic nosocomial pathogens. The taxonomy of the genus Acinetobacter underwent extensive revision in the mid-1980s, and at least 32 named and unnamed species have now been described. Of these, Acinetobacter baumannii and the closely related unnamed genomic species 3 and 13 sensu Tjernberg and Ursing (13TU) are the most relevant clinically. Multiresistant strains of these species causing bacteraemia, pneumonia, meningitis, urinary tract infections and surgical wound infections have been isolated from hospitalised patients worldwide. This review provides an overview of the antimicrobial susceptibilities of Acinetobacter spp. in Europe, as well as the main mechanisms of antimicrobial resistance, and summarises the remaining treatment options for multiresistant Acinetobacter infections.</description><subject>Acinetobacter</subject><subject>Acinetobacter - classification</subject><subject>Acinetobacter - drug effects</subject><subject>Acinetobacter baumannii</subject><subject>Acinetobacter Infections - epidemiology</subject><subject>Acinetobacter Infections - microbiology</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>antimicrobial resistance</subject><subject>Biological and medical sciences</subject><subject>carbapenems</subject><subject>Drug Resistance, Bacterial</subject><subject>Europe</subject><subject>Europe - epidemiology</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Pharmacology. Drug treatments</subject><subject>Population Surveillance</subject><subject>review</subject><subject>surveillance</subject><issn>1198-743X</issn><issn>1469-0691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkctOAyEUhonRWK2-gpmN7mbkNlASN7Wpl6TGjSbuCANnEprpzAhTL28vtY0ulQ2Q8_3A-UAoI7ggaVwuC8KFyrFQpKAY8wJjxWnxsYeOfgr7aU3UJJecvYzQcYxLjDFljB-iESkZJkKSIzSZtoNfeRu6ypsmCxB9HExrIevqbGp9C0NXGTtAyGLfF5lvs_k6dD2coIPaNBFOd_MYPd_Mn2Z3-eLx9n42XeS2LBXNnRN1zRnmacuUMBYYTBwujQFpK6CSWicUVDUIyixQUQLjxjnFjKhSlY3RxfbcPnSva4iDXvlooWlMC906aiGk5ILLP0EipeKc8gROtmBqOsYAte6DX5nwqQnWG716qTcW9cai3ujV33r1R4qe7e5YVytwv8GdzwSc7wATrWnqkFT6-MsJzARVOHFXW-7dN_D57wfo2eIhLVL8ehuHZP7NQ9DReki_5nwAO2jX-b-b-QJc1qpq</recordid><startdate>200408</startdate><enddate>200408</enddate><creator>Van Looveren, M.</creator><creator>Goossens, H.</creator><general>Elsevier Ltd</general><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>200408</creationdate><title>Antimicrobial resistance of Acinetobacter spp. in Europe</title><author>Van Looveren, M. ; Goossens, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5592-dd6ff4304c55396ace3e8d05aae7cbe272cd69ebfe623ce265e34add93a6b2723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Acinetobacter</topic><topic>Acinetobacter - classification</topic><topic>Acinetobacter - drug effects</topic><topic>Acinetobacter baumannii</topic><topic>Acinetobacter Infections - epidemiology</topic><topic>Acinetobacter Infections - microbiology</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>antimicrobial resistance</topic><topic>Biological and medical sciences</topic><topic>carbapenems</topic><topic>Drug Resistance, Bacterial</topic><topic>Europe</topic><topic>Europe - epidemiology</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Pharmacology. Drug treatments</topic><topic>Population Surveillance</topic><topic>review</topic><topic>surveillance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Van Looveren, M.</creatorcontrib><creatorcontrib>Goossens, H.</creatorcontrib><creatorcontrib>the ARPAC Steering Group</creatorcontrib><creatorcontrib>ARPAC Steering Group</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical microbiology and infection</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Van Looveren, M.</au><au>Goossens, H.</au><aucorp>the ARPAC Steering Group</aucorp><aucorp>ARPAC Steering Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antimicrobial resistance of Acinetobacter spp. in Europe</atitle><jtitle>Clinical microbiology and infection</jtitle><addtitle>Clin Microbiol Infect</addtitle><date>2004-08</date><risdate>2004</risdate><volume>10</volume><issue>8</issue><spage>684</spage><epage>704</epage><pages>684-704</pages><issn>1198-743X</issn><eissn>1469-0691</eissn><abstract>Bacteria of the genus Acinetobacter are ubiquitous in nature. These organisms were invariably susceptible to many antibiotics in the 1970s. Since that time, acinetobacters have emerged as multiresistant opportunistic nosocomial pathogens. The taxonomy of the genus Acinetobacter underwent extensive revision in the mid-1980s, and at least 32 named and unnamed species have now been described. Of these, Acinetobacter baumannii and the closely related unnamed genomic species 3 and 13 sensu Tjernberg and Ursing (13TU) are the most relevant clinically. Multiresistant strains of these species causing bacteraemia, pneumonia, meningitis, urinary tract infections and surgical wound infections have been isolated from hospitalised patients worldwide. This review provides an overview of the antimicrobial susceptibilities of Acinetobacter spp. in Europe, as well as the main mechanisms of antimicrobial resistance, and summarises the remaining treatment options for multiresistant Acinetobacter infections.</abstract><cop>Oxford, UK</cop><pub>Elsevier Ltd</pub><pmid>15301671</pmid><doi>10.1111/j.1469-0691.2004.00942.x</doi><tpages>21</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1198-743X |
| ispartof | Clinical microbiology and infection, 2004-08, Vol.10 (8), p.684-704 |
| issn | 1198-743X 1469-0691 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66774647 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Acinetobacter Acinetobacter - classification Acinetobacter - drug effects Acinetobacter baumannii Acinetobacter Infections - epidemiology Acinetobacter Infections - microbiology Anti-Bacterial Agents - pharmacology Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents antimicrobial resistance Biological and medical sciences carbapenems Drug Resistance, Bacterial Europe Europe - epidemiology Humans Infectious diseases Medical sciences Microbial Sensitivity Tests Pharmacology. Drug treatments Population Surveillance review surveillance |
| title | Antimicrobial resistance of Acinetobacter spp. in Europe |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T19%3A46%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antimicrobial%20resistance%20of%20Acinetobacter%20spp.%20in%20Europe&rft.jtitle=Clinical%20microbiology%20and%20infection&rft.au=Van%20Looveren,%20M.&rft.aucorp=the%20ARPAC%20Steering%20Group&rft.date=2004-08&rft.volume=10&rft.issue=8&rft.spage=684&rft.epage=704&rft.pages=684-704&rft.issn=1198-743X&rft.eissn=1469-0691&rft_id=info:doi/10.1111/j.1469-0691.2004.00942.x&rft_dat=%3Cproquest_cross%3E17794424%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17794424&rft_id=info:pmid/15301671&rft_els_id=S1198743X14627658&rfr_iscdi=true |